These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 34692478)

  • 1. Prognostic Value of the Pretreatment Lung Immune Prognostic Index in Advanced Small Cell Lung Cancer Patients Treated With First-Line PD-1/PD-L1 Inhibitors Plus Chemotherapy.
    Li L; Pi C; Yan X; Lu J; Yang X; Wang C; Li X; Zhang S; Zhang Z; Sun Y; Hu Y
    Front Oncol; 2021; 11():697865. PubMed ID: 34692478
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non-Small Cell Lung Cancer.
    Mezquita L; Auclin E; Ferrara R; Charrier M; Remon J; Planchard D; Ponce S; Ares LP; Leroy L; Audigier-Valette C; Felip E; Zerón-Medina J; Garrido P; Brosseau S; Zalcman G; Mazieres J; Caramela C; Lahmar J; Adam J; Chaput N; Soria JC; Besse B
    JAMA Oncol; 2018 Mar; 4(3):351-357. PubMed ID: 29327044
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of the Pretreatment Lung Immune Prognostic Index with Survival Outcomes in Advanced Hepatocellular Carcinoma Patients Treated with PD-1 Inhibitors.
    Chen S; Huang Z; Jia W; Tao H; Zhang S; Ma J; Liu Z; Wang J; Wang L; Cui P; Zhang Z; Huang D; Wu Z; Zheng X; Hu Y
    J Hepatocell Carcinoma; 2020; 7():289-299. PubMed ID: 33173757
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lung immune prognostic index as a prognostic factor in patients with small cell lung cancer.
    Sonehara K; Tateishi K; Komatsu M; Yamamoto H; Hanaoka M
    Thorac Cancer; 2020 Jun; 11(6):1578-1586. PubMed ID: 32286017
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pretreatment Lung Immune Prognostic Index Is a Prognostic Marker of Chemotherapy and Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor.
    Minami S; Ihara S; Komuta K
    World J Oncol; 2019 Feb; 10(1):35-45. PubMed ID: 30834050
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of first-line PD-L1/PD-1 inhibitors in limited-stage small cell lung cancer: a multicenter propensity score matched retrospective study.
    Xie J; Xu K; Cai Z; Chen M; Jiang Y; Ye J; Lin X; Lv T; Zhan P
    Transl Lung Cancer Res; 2024 Mar; 13(3):526-539. PubMed ID: 38601454
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Predictive Value of Pretreatment Lactate Dehydrogenase and Derived Neutrophil-to-Lymphocyte Ratio in Advanced Non-Small Cell Lung Cancer Patients Treated With PD-1/PD-L1 Inhibitors: A Meta-Analysis.
    Zhang Q; Gong X; Sun L; Miao L; Zhou Y
    Front Oncol; 2022; 12():791496. PubMed ID: 35924149
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predicting Immunotherapy Outcomes in Older Patients with Solid Tumors Using the LIPI Score.
    Pierro M; Baldini C; Auclin E; Vincent H; Varga A; Martin Romano P; Vuagnat P; Besse B; Planchard D; Hollebecque A; Champiat S; Marabelle A; Michot JM; Massard C; Mezquita L
    Cancers (Basel); 2022 Oct; 14(20):. PubMed ID: 36291861
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical Significance of Serum Biomarkers in Stage IV Non-Small-Cell Lung Cancer Treated with PD-1 Inhibitors: LIPI Score, NLR, dNLR, LMR, and PAB.
    Chen J; Wei S; Zhao T; Zhang X; Wang Y; Zhang X
    Dis Markers; 2022; 2022():7137357. PubMed ID: 35945957
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of the prognostic nutrition index as a predictive biomarker in small-cell lung cancer patients undergoing immune checkpoint inhibitor treatment in the Chinese alpine region.
    Wu Y; Yang J; Qiao X; Li Y; Zhao R; Lin T; Li X; Wang M
    Front Oncol; 2023; 13():1041140. PubMed ID: 37007079
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pretreatment lung immune prognostic index as a biomarker in advanced non-small-cell lung cancer patients receiving first line pembrolizumab.
    Veccia A; Sforza V; Vattemi E; Inno A; Kinspergher S; Dipasquale M; Gori S; Morabito A; Baldi I; Caffo O
    Immunotherapy; 2021 Sep; 13(13):1093-1103. PubMed ID: 34190578
    [TBL] [Abstract][Full Text] [Related]  

  • 12. On-treatment lung immune prognostic index is predictive for first-line PD-1 inhibitor combined with chemotherapy in patients with non-small cell lung cancer.
    Xiong A; Xu J; Wang S; Zhong R; Lu J; Chu T; Zhang W; Li Y; Zheng X; Han B; Nie W; Zhong H; Zhang X
    Front Immunol; 2023; 14():1173025. PubMed ID: 37304273
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of the pretreatment lung immune prognostic index with survival outcomes in advanced gastric cancer patients treated with immune checkpoint inhibitors.
    Hou B; Wang P; Liu T; Chen S; Li T; Zhang S; Tao H; Li X; Hu Y
    Clin Res Hepatol Gastroenterol; 2021 Sep; 45(5):101748. PubMed ID: 34182184
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic role of pretreatment lung immune prognostic index in extensive-stage small-cell lung cancer treated with platinum plus etoposide chemotherapy.
    Qi W; Zhao S; Chen J
    Cancer Biomark; 2021; 31(2):177-185. PubMed ID: 33896825
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-World Data on Pembrolizumab for Pretreated Non-Small-Cell Lung Cancer: Clinical Outcome and Relevance of the Lung Immune Prognostic Index.
    Ortega-Franco A; Hodgson C; Raja H; Carter M; Lindsay C; Hughes S; Cove-Smith L; Taylor P; Summers Y; Blackhall F; Califano R
    Target Oncol; 2022 Jul; 17(4):453-465. PubMed ID: 35781861
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of a Systemic Inflammatory Biomarker in Advanced Bile Tract Carcinoma Treated with Anti-PD-1 Therapy: Prognostic and Predictive Significance of Lung Immune Prognostic Index Score.
    Pan Y; Si H; Jia R; Deng G; Yan H; Fan M; Gou M; Chen S; Zhang N; Shi Y; Qian N; Dai G
    J Oncol; 2022; 2022():1427779. PubMed ID: 35342416
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Correlation of Lung Immune Prognostic Index With Efficacy of PD-1/PD-L1 Inhibitor Combined With Chemotherapy and Prognosis in Patients With Advanced Non-Small Cell Lung Cancer.
    Zhu Z; Zhang A
    Am J Clin Oncol; 2023 Nov; 46(11):496-502. PubMed ID: 37621004
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of the pretreatment lung immune prognostic index with immune checkpoint inhibitor outcomes in patients with advanced hepatocellular carcinoma.
    Sun T; Guo Y; Sun B; Chen L; Ren Y; Zhu L; Zhang L; Liu Y; Zheng C
    Eur J Med Res; 2023 Jul; 28(1):225. PubMed ID: 37408056
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preoperative lung immune prognostic index predicts survival in patients with pancreatic cancer undergoing radical resection.
    Zhou Q; Deng G; Wang Z; Dai G
    Front Surg; 2022; 9():1002075. PubMed ID: 36684178
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association Between Lung Immune Prognostic Index and Durvalumab Consolidation Outcomes in Patients With Locally Advanced Non-Small-Cell Lung Cancer.
    Riudavets M; Auclin E; Mosteiro M; Dempsey N; Majem M; Prelaj A; López-Castro R; Bosch-Barrera J; Pilotto S; Escalera E; Tagliamento M; Mosquera J; Zalcman G; Aboubakar Nana F; Ponce S; Albarrán-Artahona V; Dal Maso A; Spotti M; Mielgo X; Mussat E; Reyes R; Benítez JC; Lupinacci L; Duchemann B; De Giglio A; Blaquier JB; Audigier-Valette C; Scheffler M; Nadal E; Lopes G; Signorelli D; Garcia-Campelo R; Menis J; Bluthgen V; Campayo M; Recondo G; Besse B; Mezquita L; Planchard D
    Clin Lung Cancer; 2024 May; 25(3):233-243.e8. PubMed ID: 38105153
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.